arrow
D

Dimitrios Rikos

404 military hospital
H指数:12
被引数:539

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group

曲普坦85 mg/萘普生钠500 mg联合治疗急性偏头痛的疗效与安全性:GRASP研究小组的前瞻性真实世界证据

2026-07-300
OA
Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group

比较抗CGRP单克隆抗体与托吡酯在偏头痛预防中的疗效与安全性:GRASP研究小组提供的为期六个月、真实世界、意向性治疗回顾性证据

2026-04-050
OAAI
Eptinezumab to prevent difficult-to-treat migraine: prospective, six-month, real-world multicenter evidence from the GRASP study group

Eptinezumab预防难以治疗的偏头痛: 来自GRASP研究组的前瞻性,六个月,真实世界的多中心证据

2026-01-230
OAAI
Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Real-World Data From the GRASP Study Group

暂停和重新启动Fremanezumab治疗对预防难治性偏头痛的24个月连续治疗效果:GRASP研究组的回顾性、多中心、真实世界数据

2025-08-140
PREAI
Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry

更年期及其对fremanezumab预防偏头痛的有效性的影响: 前瞻性,现实世界希腊注册表的事后分析

2024-09-160
PRE
Preferences and perceptions of 617 migraine patients on acute and preventive migraine treatment attributes and clinical trial endpoints

617偏头痛患者对急性和预防性偏头痛治疗属性和临床试验终点的偏好和看法

2024-06-136
PRE
Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment Options

对2565名希腊偏头痛患者进行的基于网络的调查结果2023年: 新治疗方案时代的人口统计数据,施加的负担和对急性和预防性治疗的满意度

2024-05-084
OAAI
Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic Migraine

连续9个月的Fremanezumab预防对曲坦的反应以及高频发作性偏头痛患者的触发,超敏反应和前驱症状的发生率

2024-01-103
OAAI
Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry

Fremanezumab对难以治疗的慢性偏头痛患者的精神病合并症的影响: 前瞻性,多中心,现实世界希腊注册表的事后分析

2023-07-069
OAAI